Richter And Bio-Thera Shake Hands On $100m+ European Ustekinumab Deal
Hikma Remains Licensee Of BAT2206 Stelara Biosimilar In The US
Gedeon Richter and Bio-Thera Solutions have announced a European licensing deal worth potentially more than $100m for the Chinese biosimilar developer’s BAT2206 proposed rival to Stelara.
